{"id":"NCT05219253","sponsor":"GlaxoSmithKline","briefTitle":"A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India","officialTitle":"A Phase 3, Randomised, Observer-blind, Placebo-controlled, Multi-centre Study to Evaluate the Immune Response and Safety of the Herpes Zoster Subunit Vaccine When Administered Intramuscularly on a 2-dose Schedule in Adults Aged 50 Years and Older in India","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-02-02","primaryCompletion":"2022-10-11","completion":"2022-12-12","firstPosted":"2022-02-02","resultsPosted":"2024-04-08","lastUpdate":"2025-05-15"},"enrollment":288,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"HZ/su","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"HZ/su Group","type":"EXPERIMENTAL"},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the humoral immunogenicity and safety of 2 doses of GSK Biologicals' Herpes Zoster subunit vaccine (HZ/su) administered for the prevention of Herpes Zoster (HZ) in adults aged 50 years of age (YOA) or older from India.","primaryOutcome":{"measure":"Percentage of Participants Showing a Vaccine Response for Anti-glycoprotein E (gE)","timeFrame":"At 1 month post-Dose 2 of study intervention administration (Month 3)","effectByArm":[{"arm":"HZ/suSeq Group","deltaMin":85.7,"sd":null},{"arm":"Placebo Group","deltaMin":7.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":9,"countries":["India"]},"refs":{"pmids":["39923547","37781954"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":143},"commonTop":["Administration site pain","Fatigue","Headache","Pyrexia","Pruritus"]}}